HIV patients may soon get long-acting shots at any day hospital

NCT ID NCT06159894

Completed Knowledge-focused Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether people with HIV can receive their long-acting injectable medication at general day hospitals instead of only at specialized HIV clinics. 90 patients who were already prescribed the injections were randomly assigned to one of the two settings. The main goal was to see how acceptable patients found the experience after 12 months, using a questionnaire. The study did not test the drug itself, only the location where it is given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir and rilpivirine (long-acting injectable HIV medication)
What this could lead to: If successful, this could show that people with HIV can get their long-acting injections at regular day hospitals, making treatment more convenient and accessible.
What could go wrong: This is a small, completed study that only measures patient acceptance, not health outcomes. Results may not apply to all settings or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Fundación Jimenez Díaz

Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.